The 7 major Angelman syndrome markets size reached a value of US$ 105.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 165.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034.In 2025, the Angelman syndrome market is expected to change with increased awareness, improved identification of cases, alongside advancing scientific innovation taking the frontline. Angelman syndrome, a neurogenic disorder characterized by alteration of specific genes often results due to disrupted gene function triggering communication issues along with other difficulties pertaining to motor skills, controlling behaviors etc. The market is emerging in response to unfulfilled needs driven by therapy innovation coupled with better diagnostics.
An increase in case detection has emerged as recent years market drivers’ recommendation supporting diagnosis of the condition. More genetic screening as well as counseling programs have led physicians to accurately identify Angelman syndrome in children suffering from developmental delays because they can now support them during their early years. There's a lot of potential with therapy development in 2025. Clinical studies are progressing with gene modulation strategies such as antisense drugs and gene replacement therapies. These methods seek to enhance the expression of the functional UBE3A gene in nerve cells, which is intended to improve neurological function. Should they succeed, these approaches would represent a major shift towards truly modified intervention, instead of merely managing disease symptoms.
Request for a sample of this report: https://www.imarcgroup.com/angelman-syndrome-market/requestsample
Countries Covered:
United States
Germany
France
United Kingdom
Italy
Spain
Japan
This report also provides a detailed analysis of the current Angelman syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs:
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Competitive Landscape with key players:
The competitive landscape of the Angelman syndrome market has been studied in the report with the detailed profiles of the key players operating in the market.
1. Ionis Pharmaceuticals
2. Ultragenyx Pharmaceutical Inc
3. Neuren Pharmaceuticals
4. Roche
5. Sanofi-Aventis/UCB
6. Revolo Biotherapeutics
7. Regeneron Pharmaceuticals
8. Allergy Therapeutics
9. Inmunotek
Ask the Analyst for Customization and Explore the Full Report with TOC: Angelman Syndrome Treatment Market Epidemilogy
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145